背景:近年来,中药麻黄用于肥胖症的治疗并有一定的效果,但麻黄对围绝经期妇女的肥胖是否有效有待研究.目的:观察口服麻黄水煎剂对去卵巢肥胖大鼠体质量、血脂、血糖及激素水平的影响.设计:完全随机分组设计,对照实验.单位:兰州大学基础医学院生理学和心理学研究所.材料:实验于2006-02/06在甘肃省新药临床前研究重点实验室和兰州大学基础医学院生理学和心理学研究所实验室完成.选用健康雌性SD大鼠44只,随机分为4组,每组11只,分别为假手术组,去卵巢组,雌激素替代治疗组和麻黄组.方法:①大鼠用氯胺酮(110 mg/kg)麻醉,除假手术组外全部行双侧去卵巢术.假手术组进行同样的手术过程,但不切除卵巢.②假手术组和去卵巢组大鼠术后每天皮下注射芝麻油(0.2 mL/只),持续到实验结束.③雌激素替代治疗组大鼠术后每天皮下注射雌激素(1 mg/kg),持续到实验结束.④麻黄组大鼠术后自然口服1%浓度的麻黄水煎剂,到第6天浓度逐渐增至8%,持续到实验结束.⑤每天测定大鼠的摄食量,每隔10天测定大鼠的体质量.⑥实验结束时,所有实验动物禁食12 h后,颈动脉取血测定血清指标.同时测定体质量和体长计算李氏指数[(g)×103/体长(cm)].主要观察指标:①不同时间点各组大鼠体质量及李氏指数.②不同时间点各组大鼠摄食量结果.③大鼠血脂和血糖水平.④不同组别大鼠血清雌激素、孕激素和胰岛素水平. 结果:大鼠44只全部进入结果分析.①不同时间点各组大鼠体质量及李氏指数结果:去卵巢组大鼠实验开始第20,30,40,50天体质量分别为(256.4±14.3),(271.3±16.1),(276.4±12.7),(285.7±24.2)g,均大于假手术组大鼠相应时间点[(226.5±11.5),(241.8±12.6),(243.1±13.5),(251.1±22.4)g,P＜0.05～0.01],李氏指数大于假手术组(317.2±13.5,280.4±11.2,P＜0.01).雌激素替代治疗组实验开始第40,50天体质量分别为(243.7±14.8),(246.2±11.9)g,低于去卵巢组相应时间点(P＜0.05～0.01),李氏指数为289.9±13.5,小于去卵巢组(P＜0.01).麻黄组大鼠实验开始第40,50天体质量分别为(245.4±14.1),(252.4±14.9)g,李氏指数为294.4±11.0,小于去卵巢组(P＜0.05).②不同时间点各组大鼠摄食量结果:麻黄组大鼠实验开始第30,40,50天摄食量分别为(17.8±2.4),(22.3±3.9),(26.1±3.5)g/d,与去卵巢组比减少[(25.9±4.7),(28.5±5.3),(32.8±5.5)g/d,P＜0.05].③大鼠血脂和血糖水平:去卵巢组大鼠血清三酰甘油、胆固醇、低密度脂蛋白胆固醇含量分别为(1.73±0.32),(1.45±0.50),(0.78±0.19)mmol/L,高于假手术组[(0.94±0.29),(1.05±0.30),(0.08±0.11)mmol/L,P＜0.01].雌激素替代治疗后三酰甘油、胆固醇、低密度脂蛋白胆固醇含量及血糖浓度分别为(1.10±0.34),(1.14±0.30),(0.17±0.05),(5.88±1.21)mmol/L,低于去卵巢组(P＜0.05～0.01),高密度脂蛋白胆固醇含量高于去卵巢组[(1.11±0.31),(0.88±0.21)mmol/L,P＜0.05].麻黄组三酰甘油、胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇含量分别为(0.97±0.16),(1.11±0.20),(0.59±0.07),(0.45±0.061)mmol/L,低与去卵巢组(P＜0.05～0.01).④不同组别大鼠血清雌激素、孕激素和胰岛素水平:去卵巢组大鼠雌激素、孕激素水平分别为(17.09±9.00)ng/L,(28.51±7.99)μg/L,低于假手术组[(58.69±12.11)ng/L,(62.73±10.93)μg/L,P＜0.01],胰岛素含量高于假手术组[(31.74±6.69),(23.75±6.66)mU/L,P＜0.01].雌激素替代治疗组及和麻黄组雌激素水平为(36.03±8.83),(30.18±8.61)ng/L,高于去卵巢组(P＜0.05～0.01),胰岛素水平分别为(21.34±4.57),(24.86±6.20)mU/L,低于去卵巢组(P＜0.05～0.01),麻黄组孕激素水平为(17.68±6.19)μg/L,低于去卵巢组(P＜0.01).结论:麻黄能明显降低去卵巢肥胖大鼠的体质量,降低血脂和胰岛素水平,增加血中雌激素水平.
揹景:近年來,中藥痳黃用于肥胖癥的治療併有一定的效果,但痳黃對圍絕經期婦女的肥胖是否有效有待研究.目的:觀察口服痳黃水煎劑對去卵巢肥胖大鼠體質量、血脂、血糖及激素水平的影響.設計:完全隨機分組設計,對照實驗.單位:蘭州大學基礎醫學院生理學和心理學研究所.材料:實驗于2006-02/06在甘肅省新藥臨床前研究重點實驗室和蘭州大學基礎醫學院生理學和心理學研究所實驗室完成.選用健康雌性SD大鼠44隻,隨機分為4組,每組11隻,分彆為假手術組,去卵巢組,雌激素替代治療組和痳黃組.方法:①大鼠用氯胺酮(110 mg/kg)痳醉,除假手術組外全部行雙側去卵巢術.假手術組進行同樣的手術過程,但不切除卵巢.②假手術組和去卵巢組大鼠術後每天皮下註射芝痳油(0.2 mL/隻),持續到實驗結束.③雌激素替代治療組大鼠術後每天皮下註射雌激素(1 mg/kg),持續到實驗結束.④痳黃組大鼠術後自然口服1%濃度的痳黃水煎劑,到第6天濃度逐漸增至8%,持續到實驗結束.⑤每天測定大鼠的攝食量,每隔10天測定大鼠的體質量.⑥實驗結束時,所有實驗動物禁食12 h後,頸動脈取血測定血清指標.同時測定體質量和體長計算李氏指數[(g)×103/體長(cm)].主要觀察指標:①不同時間點各組大鼠體質量及李氏指數.②不同時間點各組大鼠攝食量結果.③大鼠血脂和血糖水平.④不同組彆大鼠血清雌激素、孕激素和胰島素水平. 結果:大鼠44隻全部進入結果分析.①不同時間點各組大鼠體質量及李氏指數結果:去卵巢組大鼠實驗開始第20,30,40,50天體質量分彆為(256.4±14.3),(271.3±16.1),(276.4±12.7),(285.7±24.2)g,均大于假手術組大鼠相應時間點[(226.5±11.5),(241.8±12.6),(243.1±13.5),(251.1±22.4)g,P＜0.05～0.01],李氏指數大于假手術組(317.2±13.5,280.4±11.2,P＜0.01).雌激素替代治療組實驗開始第40,50天體質量分彆為(243.7±14.8),(246.2±11.9)g,低于去卵巢組相應時間點(P＜0.05～0.01),李氏指數為289.9±13.5,小于去卵巢組(P＜0.01).痳黃組大鼠實驗開始第40,50天體質量分彆為(245.4±14.1),(252.4±14.9)g,李氏指數為294.4±11.0,小于去卵巢組(P＜0.05).②不同時間點各組大鼠攝食量結果:痳黃組大鼠實驗開始第30,40,50天攝食量分彆為(17.8±2.4),(22.3±3.9),(26.1±3.5)g/d,與去卵巢組比減少[(25.9±4.7),(28.5±5.3),(32.8±5.5)g/d,P＜0.05].③大鼠血脂和血糖水平:去卵巢組大鼠血清三酰甘油、膽固醇、低密度脂蛋白膽固醇含量分彆為(1.73±0.32),(1.45±0.50),(0.78±0.19)mmol/L,高于假手術組[(0.94±0.29),(1.05±0.30),(0.08±0.11)mmol/L,P＜0.01].雌激素替代治療後三酰甘油、膽固醇、低密度脂蛋白膽固醇含量及血糖濃度分彆為(1.10±0.34),(1.14±0.30),(0.17±0.05),(5.88±1.21)mmol/L,低于去卵巢組(P＜0.05～0.01),高密度脂蛋白膽固醇含量高于去卵巢組[(1.11±0.31),(0.88±0.21)mmol/L,P＜0.05].痳黃組三酰甘油、膽固醇、低密度脂蛋白膽固醇、高密度脂蛋白膽固醇含量分彆為(0.97±0.16),(1.11±0.20),(0.59±0.07),(0.45±0.061)mmol/L,低與去卵巢組(P＜0.05～0.01).④不同組彆大鼠血清雌激素、孕激素和胰島素水平:去卵巢組大鼠雌激素、孕激素水平分彆為(17.09±9.00)ng/L,(28.51±7.99)μg/L,低于假手術組[(58.69±12.11)ng/L,(62.73±10.93)μg/L,P＜0.01],胰島素含量高于假手術組[(31.74±6.69),(23.75±6.66)mU/L,P＜0.01].雌激素替代治療組及和痳黃組雌激素水平為(36.03±8.83),(30.18±8.61)ng/L,高于去卵巢組(P＜0.05～0.01),胰島素水平分彆為(21.34±4.57),(24.86±6.20)mU/L,低于去卵巢組(P＜0.05～0.01),痳黃組孕激素水平為(17.68±6.19)μg/L,低于去卵巢組(P＜0.01).結論:痳黃能明顯降低去卵巢肥胖大鼠的體質量,降低血脂和胰島素水平,增加血中雌激素水平.
배경:근년래,중약마황용우비반증적치료병유일정적효과,단마황대위절경기부녀적비반시부유효유대연구.목적:관찰구복마황수전제대거란소비반대서체질량、혈지、혈당급격소수평적영향.설계:완전수궤분조설계,대조실험.단위:란주대학기출의학원생이학화심이학연구소.재료:실험우2006-02/06재감숙성신약림상전연구중점실험실화란주대학기출의학원생이학화심이학연구소실험실완성.선용건강자성SD대서44지,수궤분위4조,매조11지,분별위가수술조,거란소조,자격소체대치료조화마황조.방법:①대서용록알동(110 mg/kg)마취,제가수술조외전부행쌍측거란소술.가수술조진행동양적수술과정,단불절제란소.②가수술조화거란소조대서술후매천피하주사지마유(0.2 mL/지),지속도실험결속.③자격소체대치료조대서술후매천피하주사자격소(1 mg/kg),지속도실험결속.④마황조대서술후자연구복1%농도적마황수전제,도제6천농도축점증지8%,지속도실험결속.⑤매천측정대서적섭식량,매격10천측정대서적체질량.⑥실험결속시,소유실험동물금식12 h후,경동맥취혈측정혈청지표.동시측정체질량화체장계산리씨지수[(g)×103/체장(cm)].주요관찰지표:①불동시간점각조대서체질량급리씨지수.②불동시간점각조대서섭식량결과.③대서혈지화혈당수평.④불동조별대서혈청자격소、잉격소화이도소수평. 결과:대서44지전부진입결과분석.①불동시간점각조대서체질량급리씨지수결과:거란소조대서실험개시제20,30,40,50천체질량분별위(256.4±14.3),(271.3±16.1),(276.4±12.7),(285.7±24.2)g,균대우가수술조대서상응시간점[(226.5±11.5),(241.8±12.6),(243.1±13.5),(251.1±22.4)g,P＜0.05～0.01],리씨지수대우가수술조(317.2±13.5,280.4±11.2,P＜0.01).자격소체대치료조실험개시제40,50천체질량분별위(243.7±14.8),(246.2±11.9)g,저우거란소조상응시간점(P＜0.05～0.01),리씨지수위289.9±13.5,소우거란소조(P＜0.01).마황조대서실험개시제40,50천체질량분별위(245.4±14.1),(252.4±14.9)g,리씨지수위294.4±11.0,소우거란소조(P＜0.05).②불동시간점각조대서섭식량결과:마황조대서실험개시제30,40,50천섭식량분별위(17.8±2.4),(22.3±3.9),(26.1±3.5)g/d,여거란소조비감소[(25.9±4.7),(28.5±5.3),(32.8±5.5)g/d,P＜0.05].③대서혈지화혈당수평:거란소조대서혈청삼선감유、담고순、저밀도지단백담고순함량분별위(1.73±0.32),(1.45±0.50),(0.78±0.19)mmol/L,고우가수술조[(0.94±0.29),(1.05±0.30),(0.08±0.11)mmol/L,P＜0.01].자격소체대치료후삼선감유、담고순、저밀도지단백담고순함량급혈당농도분별위(1.10±0.34),(1.14±0.30),(0.17±0.05),(5.88±1.21)mmol/L,저우거란소조(P＜0.05～0.01),고밀도지단백담고순함량고우거란소조[(1.11±0.31),(0.88±0.21)mmol/L,P＜0.05].마황조삼선감유、담고순、저밀도지단백담고순、고밀도지단백담고순함량분별위(0.97±0.16),(1.11±0.20),(0.59±0.07),(0.45±0.061)mmol/L,저여거란소조(P＜0.05～0.01).④불동조별대서혈청자격소、잉격소화이도소수평:거란소조대서자격소、잉격소수평분별위(17.09±9.00)ng/L,(28.51±7.99)μg/L,저우가수술조[(58.69±12.11)ng/L,(62.73±10.93)μg/L,P＜0.01],이도소함량고우가수술조[(31.74±6.69),(23.75±6.66)mU/L,P＜0.01].자격소체대치료조급화마황조자격소수평위(36.03±8.83),(30.18±8.61)ng/L,고우거란소조(P＜0.05～0.01),이도소수평분별위(21.34±4.57),(24.86±6.20)mU/L,저우거란소조(P＜0.05～0.01),마황조잉격소수평위(17.68±6.19)μg/L,저우거란소조(P＜0.01).결론:마황능명현강저거란소비반대서적체질량,강저혈지화이도소수평,증가혈중자격소수평.
BACKGROUND: Ephedra, a Chinese medicine, is often used to treat obesity with relatively satisfying results recently. However, the effects of Ephedra on the perimenopausal and postmenopausal obese women remain unclear.OBJECTIVE: To observe the effects of oral Ephedra decoction on body mass and the levels of blood lipids, blood glucose and hormone in ovarietomized obese rats.DESIGN: A completely randomized and controlled experiment.SETTING: Institute of Physiology and Psychology, School of Basic Medical Sciences, Lanzhou University.MATERIALS: The experiment was performed in the Key Laboratory of Pre-clinical Study for New Drugs of Gansu Province and the Laboratory of Institute of Physiology and Psychology, School of Basic Medical Sciences,Lanzhou University from February 2006 to June 2006. Forty-four healthy female SD rats were randomly divided into four groups with 11 rats in each group, namely sham-operated group, ovariectomized group, estrogen replacement therapy group and Ephedra group.METHODS: ① After having been narcotized by cloraminone (110 mg/kg),rats were underwent a bilateral ovariectomy except those in the sham-operated group, which were also operated, but their ovaries were not cut off. ②Rats in the sham-operated group and ovariectomized group were subcutaneously injected with sesame oil (0.2 mL/each rat) every day postoperatively till the end of the experiment. ③ The rats in the estrogen replacement therapy group were given estradiol (1 mg/kg) by subcutaneous injection every day postoperatively till the end of the experiment. ④ The rats in the Ephedra group freely drank 1% water extracts from Ephedra postoperatively, later the concentration of Ephedra gradually increased to 8% on the sixth day, which lasted until the end of the experiment. ⑤ The food intake was monitored daily, and body mass was measured every ten days. ⑥ At the end of the experiment, all the rats were fasted for 12 hours and collected blood samples for the measurement of serum indexes. The body mass and body length were measured to calculate the Lee's index [(g)×103/body length (cm)] at the same time.MAIN OUTCOME MEASURES: ① Body mass and Lee's index at different time points in each group. ② Food intake at different time points in each group. ③ Levels of blood lipids and blood glucose in each group. ④Levels of estrogen, progesterone and insulin in each group.RESULTS: Forty-four rats all entered the analysis of results. ① Result of body mass and Lee's index at different time points: The body masses on the 20th, 30th, 40th and 50th days in the ovariectomized group were (256.4±14.3),(271.3±16.1), (276.4±12.7), (285.7±24.2) g, which were significantly higher than those in the sham-operated group [(226.5±11.5), (241.8±12.6),(243.1±13.5), (251.1±22.4) g, P ＜ 0.05-0.01], and the Lee's index in the ovariectomized group was greater than that in the sham-operated group(317.2±13.5, 280.4±11.2, P ＜ 0.01). The body masses on the 40th and 50th days in the estrogen replacement therapy group were (243.7±14.8) and(246.2±11.9) g, which were significantly lower than those in the ovariectomized group (P ＜ 0.05-0.01), and the Lee's index (289.9±13.5) was lower than that in the ovariectomized group (P ＜ 0.01). The body masses on the 40th and 50th days in the Ephedra group were (245.4 ±14.1) and(252.4±14.9) g, and the Lee's index was 294.4±11.0, which were all lower than those in the ovariectomized group (P ＜ 0.05). ② Result of Food in take at different time points: The food intakes on the 30th, 40th and 50th days in the Ephedra group were (17.8±2.4), (22.3±3.9), (26.1±3.5) g per day,which were decreased as compared with those in the ovariectomized group[(25.9±4.7), (28.5±5.3), (32.8±5.5) g per day, P ＜ 0.05]. ③ Levels of blood lipids and blood glucose: The levels of triglyceride, cholesterol and low density lipoprotein cholesterol (LDL-C) in the ovariectomized group were (1.73±0.32), (1.45±0.50), (0.78±0.19) mmol/L, which were higher than those in the sham-operated group [(0.94±0.29), (1.05±0.30), (0.08±0.11) mmol/L, P ＜ 0.01]. After the estrogen replacement therapy, the levels of triglyceride, cholesterol, LDL-C and blood glucose were (1.10±0.34),(1.14±0.30), (0.17±0.05), (5.88±1.21) mmol/L, which were lower than those in the ovariectomized group (P ＜ 0.05-0.01), but the level of high density lipoprotein cholesterol (HDL-C) was higher than that in the ovariectomized group [(1.11±0.31), (0.88±0.21) mmol/L, P ＜ 0.05]. The levels of triglyceride, cholesterol, LDL-C and HDL-C in the Ephedra group were (0.97±0.16), (1.11±0.20), (0.59±0.07) and (0.45±0.061) mmol/L, which were lower than those in the ovariectomized group (P ＜ 0.05-0.01). ④ The serum levels of estrogen, progesterone and insulin in each group: The serum levels of estrogen and progesterone in the ovariectomized group were lower than those in the sham-operated group [(17.09±9.00), (28.51 ±7.99) μg/L;(58.69±12.11), (62.73±10.93) μg/L, P ＜ 0.01], the serum level of insulin was higher than that in the sham-operated group [(31.74±6.69),(23.75±6.66) mU/L, P ＜ 0.01]. The serum levels of estrogen in the estro gen replacement therapy and Ephedra group were (36.03±8.83) and (30.18±8.61) ng/L, which were higher than those in the ovariectomized group(P ＜ 0.05-0.01), the level of insulin were (21.34±4.57), (24.86±6.20) mU/L,which were lower than those in the ovariectomized group (P ＜ 0.05-0.01).The serum level of progesterone in the Ephedra group [(17.68±6.19) μg/L]was lower than that in the ovariectomized group (P ＜ 0.01).CONCLUSION: Ephedra can promote loss of body mass, reduce levels of the blood lipids and insulin, and increase the serum levels of hormones in ovariectomized obese rats.
